ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study With CC-10004 in Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00456092
Recruitment Status : Completed
First Posted : April 4, 2007
Last Update Posted : December 17, 2013
Sponsor:
Information provided by (Responsible Party):
Celgene ( Celgene Corporation )

April 2, 2007
April 4, 2007
December 17, 2013
January 2009
May 2009   (Final data collection date for primary outcome measure)
American College of Rheumatology Criteria for 20% improvement (ACR 20) [ Time Frame: Up to Day 169 ]
Proportion of participants who achieve ACR 20
Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline
Complete list of historical versions of study NCT00456092 on ClinicalTrials.gov Archive Site
  • Number of Participants with AEs [ Time Frame: Up to Day 169 ]
    Type, frequency, severity and relationship of adverse events to CC-10004
  • Number of participants prematurely discontinuing due to AEs [ Time Frame: Up to Day 169 ]
    Number of participants prematurely discontinuing due to any adverse event during all phases of treatment
  • Number of clinically significant changes AEs associated events related to a physical examination, vital signs, electrocardiogram (ECG) and/or laboratory findings [ Time Frame: Up to Day 169 ]
    Frequency of clinically significant changes AEs associated with a physical examination, vital signs, electrocardiogram (ECG) and/or laboratory findings during all treatment phases
  • The frequency that a participant is unable to withstand dose titration. [ Time Frame: Up to Day 169 ]
    Frequency of participants unable to withstand dose titration during the during all treatment periods
  • The frequency of participants who discontinue due to inability to withstand study medication adverse effects [ Time Frame: Up to Day 85& 169 ]
    Frequency of participants who discontinue due to inability to withstand study medication adverse effects during any treatment period
  • Psoriatic Arthritis Response Criteria (PsARC) [ Time Frame: Up to Day 85 & 169 ]
    Proportion of participants who meet PsARC, from baseline to Day 169
  • American College of Rheumatology Criteria for 50% improvement (ACR 50) [ Time Frame: Up to Day 85& 169 ]
    Proportion of participants who achieve ACR 50, from baseline to Day 169
  • American College of Rheumatology Criteria for 70% improvement (ACR 70) [ Time Frame: Up to Day 85 & 169 ]
    Proportion of participants who achieve ACR 70 from baseline to Day 169
  • American College of Rheumatology Criteria for 90% improvement (ACR 90) [ Time Frame: Up to Day 85 &169 ]
    Proportion of participants who achieve ACR 90 from baseline to Day 169
  • Change in Disease Activity Score (DAS28) [ Time Frame: Up to Day 85 & 169 ]
    Proportion of participants who achieve a 'good' or 'moderate' response according to DAS28 from baseline to Day 169
  • Disease Activity Score (DAS28) [ Time Frame: Up to Day 85 & 169 ]
    Proportion of participants whose disease severity is 'mild' or 'in remission' according to DAS from baseline to Day 169
  • Proportion of participants who withdraw prematurely due to lack of efficacy [ Time Frame: Up to Day 169 ]
    Proportion of participants who withdraw prematurely due to lack of efficacy from baseline to Day 169
  • Proportion of participants who dose reduce [ Time Frame: Up to Day 169 ]
    Proportion of participants who dose reduce from baseline through the end of the extension phase
  • American College of Rheumatology Criteria response [ Time Frame: Up to Day 85 & 169 ]
    Maximal ACR response from baseline to the end of the extension phase
  • American College of Rheumatology Criteria for 20% improvement (ACR 20) [ Time Frame: Up to Day 85 & 169 ]
    Time to achieve ACR 20 from baseline to the end of the extension phase
  • American College of Rheumatology Criteria for 50% improvement (ACR 50) [ Time Frame: Up to Day 85 & 169 ]
    Time to achieve ACR 50 from baseline to the end of the extension phase
  • American College of Rheumatology Criteria for 70% improvement (ACR 70) [ Time Frame: Up to Day 85 & 169 ]
    Time to achieve ACR 70 from baseline to the end of the extension phase
  • American College of Rheumatology Criteria for 90% improvement (ACR 90) [ Time Frame: Up to Day 85 & 169 ]
    Time to achieve ACR 90 from baseline to the end of the extension phase
  • Change in Dactylitis Score [ Time Frame: Up to Day 85 & 169 ]
    Change in dactylitis score from baseline through Day 169
  • Enthesitis incidence proportion [ Time Frame: Up to Day 85 & 169 ]
    Proportion of participants with and without enthesitis from baseline through Day 169
  • Time of Relapse of Psoriatic arthritis [ Time Frame: Up to Day 169 ]
    Time to relapse of psoriatic arthritis in participants who achieved at least an ACR 20 response from baseline through Day 169
  • Proportion of participants who relapsed during observational follow up [ Time Frame: Up to Day 169 ]
    Proportion of participants who relapsed during observational follow up
  • Change in Short Form 36 Version 2 (SF-36) [ Time Frame: Up to Day 85 & 169 ]
    Change in SF-36 Score, from baseline to Day 169
  • Change in Dermatology Life Quality Index (DLQI) [ Time Frame: Up to Day 85 & 169 ]
    Change in DLQI from baseline to Day 169
  • Change in the Health Assessment Questionnaire Disability Index (HAQ-DI) [ Time Frame: Up to Day 85 & 169 ]
    Change in HAQ-DI from baseline to Day 169
  • Change in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) [ Time Frame: Up to Day 85 & 169 ]
    Change in SF-36 from baseline to Day 169
  • Change in T cell, B cell and NK cells in peripheral blood harmacodynamic (PD) [ Time Frame: Up to Day 85 ]
    Change in T cell, B cell and NK cells in peripheral blood at Day 85, and early termination from Treatment Phase visit from baseline to Day 169
  • Change in synovitis (synovium thickness and vascularity) and inflammatory markers in synovial tissue [ Time Frame: Up to Day 85 ]
    Change in synovitis (synovium thickness and vascularity) and inflammatory markers in synovial tissue from baseline to Day 85
  • Change in epidermal thickness and inflammatory markers in psoriatic skin [ Time Frame: Up to Day 85 ]
    Change in epidermal thickness and inflammatory markers in psoriatic skin from baseline to Day 85
  • Area under the plasma concentration-time curve from time 0 to 8 hours from dosing (AUC [ Time Frame: Day 71 ]
    Area under the plasma concentration-time curve from time 0 to 8 hours from dosing (AUC)
  • Peak plasma concentration [ Time Frame: Day 71 ]
    Peak plasma concentration
  • Time to maximum plasma concentration [ Time Frame: Day 71 ]
    Time to maximum plasma concentration
  • Relationship of PK to PD and clinical outcomes) [ Time Frame: Day 71 ]
    Relationship of PK to PD and clinical outcomes
  • Type, frequency, severity and relationship of adverse events to CC-10004;
  • Number of subjects who prematurely discontinue study medication due to any adverse event;
  • Frequency of clinically significant changes in physical examination, vital signs, ECG and/or laboratory findings
  • Frequency of subjects unable to withstand dose titration
  • Frequency of subjects who discontinue participation in the treatment phase due to inability to withstand over adverse effects of the study medication;
  • Proportion of subjects in each treatment group who meet PsARC at Day 85/early termination
  • Proportion of subjects in each treatment group who achieve an ACR 50 and ACR 70 at Day 85/early termination
  • Change in DAS of subjects in each treatment group at D85/early termination
  • Change in PASI score at Day 85/ET
  • Proportion of subjects in each treatment group who achieve >= PASI 50 at D85/ET
  • Maximal ACR response during treatment
  • Maximal PASI response during treatment
  • Time to achieve ACR 20/50/70
  • Time to achieve PASI 50
  • Change in dactylitis severity score in subjects in each treatment group at D85/ET
  • Proportion of subjects with and without enthesitis in each treatment group at D85/ET
  • Time to relapse of psoriasis during observational follow up
  • Time to relapse of psoriatic arthritis during observational follow up
  • Proportion of subjects who relapse during observational follow up
  • Change from baseline in QOL assessment scores at D85/ET
  • Change in peripheral blood T cell, B cell and NK cell subsets
  • Change in synovitis and change in inflammatory markers in synovial tissue at D85/ET
  • Change in epidermal thickness and change in inflammatory markers in psoriatic skin biopsies at D85/ET
  • Pharmacokinetic profile including AUC, Cmax, Tmax and relationship of PK to PD and clinical outcomes
Not Provided
Not Provided
 
Phase II Study With CC-10004 in Psoriatic Arthritis
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of CC-10004 in Subjects With Active Psoriatic Arthritis
This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in patients with active psoriatic arthritis. The pharmacokinetics of the compound in patients will also be explored, and biopsies will be taken of the skin and the knee synovium to look at the activity of the drug in the relevant tissues.
This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in patients with active psoriatic arthritis. Participants must have a minimum of 6 months history of psoriatic arthritis to qualify. Prior to the implementation of Amendment 1/UK3 the study was in 3 phases - pre-randomisation up to 35 days, up to 84 days treatment and a 28 day follow up. After the implementation of Amendment 1/UK3, the study is in 4 phases - pre-randomization up to 35 days, up to 84 days treatment in the placebo controlled treatment phase, up to 84 days treatment in the active treatment extension phase and a 28 day follow up. Treatment groups are 40 milligrams (mg) once daily (od), 20 mg twice daily (bd) or placebo. To ameliorate the dose dependent adverse events of CC-10004 (headache and gastro-intestinal (GI) disturbances) there will be dose titration of 10mg od (or placebo) for days 1 to 3 followed by 20 mg od (or placebo) days 4 to 7 in the first week of dosing. Patients changing from placebo to active treatment on entry to the extension phase will undergo dose titration of 10mg od for days 85 to 87 followed by 20mg od days 88 to 91. Assessments take place after week 1 and then every 2 weeks during the treatment phase. Plasma pharmacokinetics of CC-10004 will be evaluated in a subset of patients from each active treatment group during the placebo controlled treatment phase. Normal and psoriatic skin biopsies and/or synovial biopsies will be taken for evaluation of histopathology and biomarkers from subsets of patients in each treatment group.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Psoriatic Arthritis
  • Drug: CC-10004
    20mg CC-10004 twice a day orally following dose titration)
    Other Name: Apremilast
  • Drug: CC-10004
    40 mg CC-10004 QD following dose titration
    Other Name: Apremilast
  • Drug: Matching Placebo
    : Placebo identical to CC-10004 orally BID or QD following dose titration
  • Experimental: Apremilast 20 mg
    20mg CC-10004 orally twice a day (BID)
    Intervention: Drug: CC-10004
  • Experimental: Apremilast 40 mg
    40 mg CC-10004 orally every day (QD)
    Intervention: Drug: CC-10004
  • Placebo Comparator: Placebo
    Matching Placebo identical to CC-10004 orally BID or QD
    Intervention: Drug: Matching Placebo
Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
204
132
May 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of psoriatic arthritis (Moll and Wright Criteria), including symmetrical or asymmetrical peripheral joint involvement for at least 6 months
  • Active psoriatic arthritis at the time of screening and baseline as defined by:

    3 or more swollen joints AND 3 or more tender joints

  • Negative rheumatoid factor (RF)
  • If using methotrexate, be on methotrexate for at least 168 days (24 weeks) and be on a stable dose for at least 56 days prior to screening and throughout the study
  • If using oral corticosteroids, be on a stable dose of prednisone ≤ 10 mg/day or equivalent for at least 28 days prior to screening and throughout the study
  • If using nonsteroidal anti-inflammatory drug (NSAID) therapy, be on a stable dose for at least 14 days prior to screening and throughout the study
  • Must meet the following laboratory criteria:

    • Hemoglobin ≥ 9 g/dL
    • Hematocrit ≥ 27%
    • White blood cell (WBC) count ≥ 3000 /μL (≥ 3.0 X 109/L) and < 20,000/μL (< 20 X 10^9/L)
    • Neutrophils ≥ 1500 /μL (≥ 1.5 X 10^9/L)
    • Platelets ≥ 100,000 /μL (≥ 100 X 10^9/L)
    • Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
    • Total bilirubin ≤ 2.0 mg/dL
    • Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) ≤ 1.5x upper limit of normal (ULN)
  • Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active FCBP must agree to use TWO adequate forms of contraception while on study medication. A FCBP must agree to have pregnancy tests every 28 days while on study medication
  • Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP while on study medication and for at least 84 days after taking the last dose of study medication

Exclusion Criteria:

History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases

  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or lactating female
  • History of active Mycobacterium tuberculosis infection (any subspecies) within 3 years prior to the screening visit. Infections that occurred > 3 years prior to entry must have been effectively treated.
  • History of incompletely treated latent Mycobacterium tuberculosis infection (as indicated by a positive Purified Protein Derivative [PPD] skin test or in vitro test [T SPOT®.TB, QuantiFERON Gold®])
  • Clinically significant abnormality on the chest x-ray (CXR) at screening
  • Current erythrodermic, guttate, or pustular forms of psoriasis
  • History of infected joint prosthesis within the past 5 years
  • Systemic therapy for psoriasis and/or psoriatic arthritis (except for methotrexate, ≤ 10 mg/day prednisone or equivalent, and NSAIDs) including, but not limited to, sulfasalazine, leflunomide, chloroquine, hydroxychloroquine, gold compounds, parenteral corticosteroids (including intra-articular), penicillamine, cyclosporine, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine, and fumaric acid esters within 28 days of randomization and throughout the study
  • Topical therapy for the treatment of psoriasis including, but not limited to topical steroids, topical vitamin A or D analog preparations, tacrolimus, pimecrolimus, or anthralin within 14 days of randomization (Note: Topical background therapy for treatment of psoriasis is allowed, except within 24 hours of a study visit, as follows: mild or moderate potency corticosteroids for treatment of the palms, face, scalp, axillae, plantar surfaces, and groin in accordance with the manufacturer's suggested usage. Nonmedicated emollients [eg, Eucerin®] and tar shampoo are also allowed.)
  • Phototherapy (ultraviolet light A [UVA], narrow-band ultraviolet light B [NB-UVB], psoralens and long-wave ultraviolet radiation [PUVA]) within 28 days prior to randomization
  • Etanercept use within 56 days prior to randomization
  • Adalimumab, efalizumab, or infliximab use within 84 days prior to randomization
  • Alefacept use within 168 days (24 weeks) prior to randomization
  • Use of intra-articular corticosteroids within 28 days prior to randomization
  • Use of any investigational medication within 28 days prior to randomization or 5 half-lives if known (whichever is longer)
  • Any clinically significant abnormality on 12-lead ECG at screening
  • High-risk factor(s) for, or a history of, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus infection
  • History of malignancy within previous 5 years (except for treated basal-cell skin carcinoma(s) and/or fewer than 3 treated squamous-cell skin carcinomas)
  • Evidence of skin conditions at the time of screening visit that would interfere with evaluations of the effect of study medication on psoriasis
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Canada,   Germany,   Netherlands,   United Kingdom
 
 
NCT00456092
CC-10004-PSA-001
Yes
Not Provided
Not Provided
Celgene ( Celgene Corporation )
Celgene Corporation
Not Provided
Principal Investigator: Edward Keystone Mount Sinai Hospital, Rebecca MacDonald Centre for Arthritis and Auto-immune disease, Toronto
Principal Investigator: Carter Thorne Arthritis Program Research Group, Ontario
Principal Investigator: Kurt de Vlam Universitaire Ziekenhuizen Leuven
Principal Investigator: P Geusens Universiteit Hasselt, Diepenbiek
Principal Investigator: Jacques Bentin CHU Brugmann Dept Rheumatology, Brussels
Principal Investigator: Rik Joos Jan Palfijn Ziekenhuis, Merksem
Principal Investigator: Georg Schett Friedrich-Alexander-University, Erlangen
Principal Investigator: Gerd Burmester Free University of Berlin
Principal Investigator: Harald Burkhardt Universitaetsklinikum Frankfurt
Principal Investigator: Holm Haentzschel Universitaet Leipzig
Principal Investigator: Martin Lorenz Universitaet Heidelberg
Principal Investigator: Andrea Rubbert Universitaetsklinik Koeln
Principal Investigator: Jan Simon Universitaetsklinikum Leipzig, Dept of Dermatology
Principal Investigator: Jurgen Wollenhaupt Klinikum Eilbek, Hamburg
Principal Investigator: Piet van Riel Radboud University
Principal Investigator: T W Huizinga Leiden University Medical Centre
Principal Investigator: H K Ronday Hagaziekenhuis, Den Haag
Principal Investigator: Paul Emery Chapel Allerton Hospital, Leeds
Principal Investigator: Robert G Cooper Hope Hospital, Salford, Manchester
Principal Investigator: Andrew Ostor Addenbrooke's Hospital, Cambridge
Principal Investigator: Bruce Kirkham Guys and St Thomas' Hospital, London
Principal Investigator: John Packham Haywood Hospital, Stoke on Trent
Principal Investigator: David Walker Freeman Hospital, Newcastle
Study Director: Wei Zhu, MD Celgene Corporation
Celgene
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP